PharmaCyte Biotech
PMCB----
PharmaCyte Biotech (PMCB)
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulat...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
- 52wk Low
- --
- Float Mkt Cap
- --
- Market Cap
- --
- P/ETTM
- --
- P/EDynamic
- --
- P/EStatic
- --
- EPSTTM
- --
- EPSDynamic
- --
- EPSStatic
- --
- BVPS
- --
- P/B
- --
- Circulating Supply
- --
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- --
- Min lot size
- --
- Currency
- --
PharmaCyte Biotech Analyst Rating
View moreForecast & Rating
Oct 7, 2022Price forecast
--100.00%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Movers ·
PharmaCyte Biotech surges 14% during regular trading
- Global Report ·
Editas' Zero Crisis Sickle Cell Therapy Ignites Biotech's Quiet Comeback
- PUBT ·
PharmaCyte Biotech Replaces CBIZ With Grassi as Auditor
- TradingView ·
PharmaCyte Biotech 2026: Revenue $0 Net income ($5.79M), EPS ($0.54) — 10-Q Summary
- PUBT ·
PharmaCyte net loss widens to $19.42 million in FY26; revenue remains no revenue
- benzinga_article ·
12 Health Care Stocks Moving In Tuesday's After-Market Session
